McMichael Andrew, Mwau Matilu, Hanke Tomás
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Vaccine. 2002 May 6;20(15):1918-21. doi: 10.1016/s0264-410x(02)00067-1.
Development of an HIV vaccine presents a formidable challenge. One of the unresolved, yet central issues is the importance of HIV variability. Here we argue that even with the recent focus on the induction of T cell-mediated immunity, HIV vaccines should match the local circulating HIV clades. Whether used alone or in a combination with vaccines eliciting HIV-neutralizing antibodies, efforts must be made to develop a T cell vaccine that stimulates a broad and long-lasting response.
开发一种HIV疫苗面临着巨大的挑战。尚未解决但核心的问题之一是HIV变异性的重要性。在此我们认为,即使近期重点关注诱导T细胞介导的免疫,HIV疫苗也应与当地流行的HIV分支相匹配。无论单独使用还是与能引发HIV中和抗体的疫苗联合使用,都必须努力开发一种能刺激广泛且持久反应的T细胞疫苗。